2种用药方案治疗小儿病毒性肺炎的成本-效果分析  

Tanreqing Injection Versus Cibavirin for Children's Viral Pneumonia:Cost-Effectiveness Analysis

作　　者：胥鹏飞[1] 魏光晨[1] 司民一[1] 刑军[1] 董传海[1] 

机构地区：[1]山东莱芜市人民医院,莱芜市271100

出　　处：《中国药房》2008年第23期1765-1766,共2页China Pharmacy

摘　　要：目的:评价痰热清和利巴韦林注射液治疗小儿病毒性肺炎的成本-效果。方法:采用回顾性分析研究方法,抽取60份小儿病毒性肺炎患者病例,其中A组30例应用痰热清注射液治疗,B组30例应用利巴韦林注射液治疗,比较2组临床疗效与不良反应,并进行成本-效果分析。结果:A、B组有效率分别为100%、80%,不良反应发生率分别为3.33%、13.33%,成本分别为297.88、399.95元,成本-效果比分别为297.88、499.94,二者之间差异均有统计学意义(P<0.05)。结论:痰热清注射液对小儿病毒性肺炎不但安全、有效,而且更加经济、合理。OBJECTIVE： To evaluate the cost-effectiveness of Tanreqing injection in treating children＇ s viral pneumonia. METHODS： In this retrospective study, sixty children with viral pneumonia were randomly assigned to receive Tanreqing Injection （treatment Group, n = 30） or Ribavirin（control Group, n = 30） . The clinical effects and adverse drug reactions （ADRs） of the two groups were compared, and the cost- effectiveness analyses were performed. RESULTS： The effective rate was 100% in the treatment Group versus 80% in the control Group; the incidence rate of ADRs was 3.33% vs. 13.33% ; the cost was 297.88 vs. 399.95 yuan; and the cost - effectiveness was 297.88 vs. 499.94, all showing significant differences between the two groups （P 〈 0.05） . CONCLUSION： Tanreqing injection is safe, effective, more economical and reasonable than Ribavirin in treating children＇s viral pneumonia.

关 键 词：小儿病毒性肺炎 痰热清注射液 利巴韦林注射液 成本-效果分析 

分 类 号：R956[医药卫生—药学] R985